<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03423901</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/17/0426</org_study_id>
    <nct_id>NCT03423901</nct_id>
  </id_info>
  <brief_title>Impact of Anti-HLA Donor-specific Antibodies in ABO-incompatible Kidney Transplantation</brief_title>
  <acronym>A3</acronym>
  <official_title>Impact of Anti-HLA Donor-specific Antibodies in ABO-incompatible Kidney Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It was previously suggested an improvement of graft survival in ABO/HLA incompatible kidney
      transplantation (KT) compared with HLA (human leukocyte antigen) incompatible
      transplantation. Here, the investigators would analyse clinical, biological and histological
      results of ABO/HLA incompatible kidney transplant recipients, comparing with ABO or HLA
      compatible kidney transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose to analyze the clinical, biological and histological course of
      kidney function, but also to investigate the T and B cells population after KT in ABO
      incompatible, ABO/HLA incompatible and HLA incompatible kidney transplantation (1 and 7 years
      posttransplantation in each groups).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2018</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gene expression related to antibody mediated rejection</measure>
    <time_frame>1 year posttransplantation</time_frame>
    <description>To determine expression of genes related to antibody mediated rejection (inflammation, and endothelial cell activation) by transcriptomic analyse (whole genome micro-array) on kidney biopsies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>description of T subsets cells</measure>
    <time_frame>1 to 5 years posttransplantation</time_frame>
    <description>to analyse of T subsets cells after Kidney transplantation in blood samples of patients by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>description of B subsets cells</measure>
    <time_frame>1 to 5 years posttransplantation</time_frame>
    <description>to analyse of B subsets cells after Kidney transplantation in blood samples of patients by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>description of lymphocytes rates</measure>
    <time_frame>1 to 5 years posttransplantation</time_frame>
    <description>to analyse rates of lymphocytes after Kidney transplantation in blood samples of patients by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of creatinine clearance</measure>
    <time_frame>1 to 5 years posttransplantation</time_frame>
    <description>to analyse creatinine clearance in blood samples of patients after kidney transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of systematic annual kidney biopsies</measure>
    <time_frame>1 to 5 years posttransplantation</time_frame>
    <description>To analyse the evolution of systematic annual kidney biopsies by microscopy</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Kidney Transplant</condition>
  <arm_group>
    <arm_group_label>ABO/HLA incompatible KT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood sampling for descriptive analysis of clinical, biological and histological of 12 ABO and HLA incompatible kidney transplantation (KT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABO incompatible KT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood sampling for descriptive analysis of clinical, biological and histological of 28 ABO incompatible kidney transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HLA incompatible KT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood sampling for descriptive analysis of clinical, biological and histological of 20 HLA incompatible kidney transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Descriptive analysis of clinical, biological and histological of 3 arms: ABO incompatible, HLA incompatible, and ABO/HLA incompatible kidney transplantation (1 and 5 years posttransplantation in each groups)</description>
    <arm_group_label>ABO/HLA incompatible KT</arm_group_label>
    <arm_group_label>ABO incompatible KT</arm_group_label>
    <arm_group_label>HLA incompatible KT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient receiving a KT and followed at least one year in Toulouse Hospital

          -  Patient who have signed informed consent

          -  &gt; 18 years old

        Exclusion Criteria:

          -  Patient under protective measures

          -  Patients treated for cancer, infectious or immune disease by molecules that could
             interfere with lymphocyte populations : Interleukin 6 (IL6) blockers, Programmed cell
             death 1(PD1) and the cytotoxic T-lymphocyte-associated antigen 4 (CTL4) blockers.

          -  Immunosuppressive treatments withdrawal - Patient in chronic dialysis

          -  Ongoing pregnancy or pregnancy in the past year

          -  Past of splenectomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnaud DEL BELLO, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arnaud DEL BELLO, MD PhD</last_name>
    <phone>0561323923</phone>
    <phone_ext>33</phone_ext>
    <email>delbello.a@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud DEL BELLO, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2018</study_first_submitted>
  <study_first_submitted_qc>February 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Complications</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

